ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsang, K.
Right arrow Articles by Tanaka, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsang, K.
Right arrow Articles by Tanaka, E
Eur Respir J 1999; 13: 361-364
Copyright © ERS Journals Ltd 1999

Clinical Trial

A pilot study of low-dose erythromycin in bronchiectasis

KW Tsang, PI Ho, KN Chan, MS Ip, WK Lam, CS Ho, KY Yuen, GC Ooi, R Amitani, and E Tanaka

Patients with bronchiectasis suffer from sputum production, recurrent exacerbations, and progressive airway destruction. Erythromycin is effective in diffuse panbronchiolitis, another suppurative airway disorder, although its efficacy is unknown in idiopathic bronchiectasis. A double-blind placebo-controlled study was therefore conducted to evaluate the effects of 8-week administration of low dose erythromycin (500 mg b.i.d.) in steady-state idiopathic bronchiectasis. Patients in the erythromycin group (n=11, 8 female, mean age 50+/-15 yrs), but not the placebo group (n=10, 8 female, mean age 59+/-16 yrs) had significantly improved forced expiratory volume in one second, forced vital capacity and 24-h sputum volume after 8 weeks (p<0.05). There was no parallel improvement in sputum pathogens, leukocytes, interleukin (IL)-1alpha and IL-8, tumour necrosis factor-alpha, or leukotriene B4. The results of this pilot study show that low-dose erythromycin improves lung function and sputum volume in bronchiectasis. Further studies are indicated to evaluate the efficacy of long-term erythromycin therapy in bronchiectasis.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
P. A. J. Crosbie and M. A. Woodhead
Long-term macrolide therapy in chronic inflammatory airway diseases
Eur. Respir. J., January 1, 2009; 33(1): 171 - 181.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. E. O'Donnell
Bronchiectasis
Chest, October 1, 2008; 134(4): 815 - 823.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. E. Stover and D. Mangino
Macrolides: A Treatment Alternative for Bronchiolitis Obliterans Organizing Pneumonia?
Chest, November 1, 2005; 128(5): 3611 - 3617.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
S C Bell, S L Senini, and J G McCormack
Macrolides in cystic fibrosis
Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98.
[Abstract] [PDF]

Home page
 ChestHome page
P. Scheinberg, E. Shore, and on behalf of the PC-TNDS-008 Study Group
A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis
Chest, April 1, 2005; 127(4): 1420 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
K W Tsang, K C Tan, P L Ho, G C Ooi, J C Ho, J Mak, G L Tipoe, C Ko, C Yan, W K Lam, et al.
Inhaled fluticasone in bronchiectasis: a 12 month study
Thorax, March 1, 2005; 60(3): 239 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. W. Amsden
Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
J. Antimicrob. Chemother., January 1, 2005; 55(1): 10 - 21.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G Davies and R Wilson
Prophylactic antibiotic treatment of bronchiectasis with azithromycin
Thorax, June 1, 2004; 59(6): 540 - 541.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
K.W. Tsang, P. Ng, P.L. Ho, S. Chan, G. Tipoe, R. Leung, J. Sun, J.C. Ho, M.S. Ip, and W.K. Lam
Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro
Eur. Respir. J., March 1, 2003; 21(3): 401 - 406.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. W. Garey, A. Alwani, L. H. Danziger, and I. Rubinstein
Tissue Reparative Effects of Macrolide Antibiotics in Chronic Inflammatory Sinopulmonary Diseases
Chest, January 1, 2003; 123(1): 261 - 265.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. F. Barker
Bronchiectasis
N. Engl. J. Med., May 2, 2002; 346(18): 1383 - 1393.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. Gorrini, A. Lupi, S. Viglio, F. Pamparana, G. Cetta, P. Iadarola, J. C. Powers, and M. Luisetti
Inhibition of Human Neutrophil Elastase by Erythromycin and Flurythromycin, Two Macrolide Antibiotics
Am. J. Respir. Cell Mol. Biol., October 1, 2001; 25(4): 492 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. F. BARKER, L. COUCH, S. B. FIEL, M. H. GOTFRIED, J. ILOWITE, K. C. MEYER, A. O'DONNELL, S. A. SAHN, L. J. SMITH, J. O. STEWART, et al.
Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis
Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 481 - 485.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. W. Tsang, K.-n. Chan, P.-l. Ho, L. Zheng, G. C. Ooi, J. C. M. Ho, and W.-k. Lam
Sputum Elastase in Steady-State Bronchiectasis
Chest, February 1, 2000; 117(2): 420 - 426.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.